Covered stent placement for treatment of coarctation of the aorta: immediate and long-term results.


Journal

Acta cardiologica
ISSN: 1784-973X
Titre abrégé: Acta Cardiol
Pays: England
ID NLM: 0370570

Informations de publication

Date de publication:
Jul 2021
Historique:
pubmed: 29 10 2020
medline: 26 11 2021
entrez: 28 10 2020
Statut: ppublish

Résumé

This study aimed to describe the safety and efficacy of covered stents in patients with coarctation of aorta (CoA) for immediate and long-term follow-up. Covered stents are increasingly being used in (re)CoA, mainly to reduce the risk of aortic wall injuries (AWI). However, limited data are available on intermediate and long-term outcome. In 89 patients (67.4% male) with a mean age of 23.9 ± 15.8 (min max range 5.1-71.6) years were 102 covered stents implanted (January 2003 - December 2017). Short-term pre/post-implant hemodynamics and angiographic data were reported. Changes in blood pressure, the use of antihypertensive drugs and complications were recorded during follow-up. The procedural success rate was 100%. The mean invasive ascending-to-descending aorta systolic gradient under general anaesthesia decreased from 25 ± 16 mmHg to 4 ± 7 mmHg ( Covered stent implantation for CoA is highly successful, safe and results in a persistent hemodynamic improvement in the immediate and long-term outcome. Lifelong follow-up with additional antihypertensive drug treatment is mandatory to maintain favourable hemodynamic results after stenting. Long-term follow-up data on covered stents in patients with coarctation of the aorta are scarce. A cohort of 89 patients was reviewed. The procedural implantation success rate was 100%. The invasive gradient decreased from 25 ± 16 mmHg to 4 ± 7 mmHg (

Sections du résumé

OBJECTIVES OBJECTIVE
This study aimed to describe the safety and efficacy of covered stents in patients with coarctation of aorta (CoA) for immediate and long-term follow-up.
BACKGROUND BACKGROUND
Covered stents are increasingly being used in (re)CoA, mainly to reduce the risk of aortic wall injuries (AWI). However, limited data are available on intermediate and long-term outcome.
METHODS METHODS
In 89 patients (67.4% male) with a mean age of 23.9 ± 15.8 (min max range 5.1-71.6) years were 102 covered stents implanted (January 2003 - December 2017). Short-term pre/post-implant hemodynamics and angiographic data were reported. Changes in blood pressure, the use of antihypertensive drugs and complications were recorded during follow-up.
RESULTS RESULTS
The procedural success rate was 100%. The mean invasive ascending-to-descending aorta systolic gradient under general anaesthesia decreased from 25 ± 16 mmHg to 4 ± 7 mmHg (
CONCLUSIONS CONCLUSIONS
Covered stent implantation for CoA is highly successful, safe and results in a persistent hemodynamic improvement in the immediate and long-term outcome. Lifelong follow-up with additional antihypertensive drug treatment is mandatory to maintain favourable hemodynamic results after stenting.
CONDENSED ABSTRACT CONCLUSIONS
Long-term follow-up data on covered stents in patients with coarctation of the aorta are scarce. A cohort of 89 patients was reviewed. The procedural implantation success rate was 100%. The invasive gradient decreased from 25 ± 16 mmHg to 4 ± 7 mmHg (

Identifiants

pubmed: 33108973
doi: 10.1080/00015385.2020.1838126
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

464-472

Auteurs

Jan Stassen (J)

Clinical Department of Cardiovascular diseases, University Hospitals Leuven, Leuven, Belgium.

Pieter De Meester (P)

Clinical Department of Cardiovascular diseases, University Hospitals Leuven, Leuven, Belgium.
Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.

Els Troost (E)

Clinical Department of Cardiovascular diseases, University Hospitals Leuven, Leuven, Belgium.

Leen Roggen (L)

Clinical Department of Cardiovascular diseases, University Hospitals Leuven, Leuven, Belgium.

Philip Moons (P)

Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
Institute of Health and Care Science, University of Gothenburg, Gothenburg, Sweden.
Department of Pediatrics and Child Health, University of Cape Town, Cape Town, South Africa.

Marc Gewillig (M)

Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
Clinical Department of Pediatric Cardiology, University Hospitals Leuven, Leuven, Belgium.

Alexander Van De Bruaene (A)

Clinical Department of Cardiovascular diseases, University Hospitals Leuven, Leuven, Belgium.
Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.

Werner Budts (W)

Clinical Department of Cardiovascular diseases, University Hospitals Leuven, Leuven, Belgium.
Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH